Anti-EGFL7 (full length) polyclonal antibody

Transplantation of endothelial cells (ECs) is a promising therapeutic approach for ischemic disorders. In addition, the generation of ECs has become increasingly important for providing vascular plexus to regenerated organs, such as the liver. Although many attempts have been made to generate ECs from pluripotent stem cells and nonvascular cells, the minimum number of transcription factors that specialize in directly inducing vascular ECs remains undefined. Here, by screening 18 transcription factors that are important for both endothelial and hematopoietic development, we demonstrate that ets variant 2 (ETV2) alone directly converts primary human adult skin fibroblasts into functional vascular endothelial cells (ETVECs). In coordination with endogenous FOXC2 in fibroblasts, transduced ETV2 elicits expression of multiple key endothelial development factors, including FLI1, ERG, and TAL1, and induces expression of endothelial functional molecules, including EGFL7 and von Willebrand factor. Consequently, ETVECs exhibits EC characteristics in vitro and forms mature functional vasculature in Matrigel plugs transplanted in NOD SCID mice. Furthermore, ETVECs significantly improve blood flow recovery in a hind limb ischemic model using BALB/c-nu mice. Our study indicates that the creation of ETVECs provides further understanding of human EC development induced by ETV2.

Objectives: The aim of this study was to investigate miR-126 for its effect on cardiac fibroblasts proliferation and regulatory mechanism. Methods: Isolation and culture of rats cardiac fibroblasts cells(CFs) were conducted and CFs in the experiment were divided into CFs, mimics, inhibitors, the NS-MiRNA group. Then relevant genetic sequences of miR-126 mimics, inhibitors and NS-the miRNA transfected into CF cells, respectively. The effect of miR-126 on the proliferation of CFs was tested by CCK8 method. And the effects of miR-126 on cell cycle of CFs were measured by flow cytometry method. Meanwhile, Immunofluorescence Tests were done for measuring the effects of miR-126 on expression of alpha-SMA and EDU. Finally, mRNA and protein expression levels of EGFL7, AKT, pAKT, ERK, pERK of each group of cells, respectively, were measured by fluorescence quantitative PCR(fqPCR) and protein printing. Results: The miR-126 agonist and inhibitor were successfully constructed, respectively. And results of CCK8 test showed that miR-126 mimics group inhibited effectively proliferation of CFs while miR-126 inhibitor group promoted the proliferation of CFs. Results of flow cytometry showed that compared with those of CFs group, cells of G1 phase in the mimics group was significantly increased(P < 0.05), but cells proportion of S phase in the mimics group reduced(P < 0.05). Compared with those of CFs group, cells of G(1) phase in the inhibitors group was significantly reduced(P < 0.05), cell proportion of S phase in the inhibitors group increased(P < 0.05), accordingly. Results of immunofluorescence test indicated that compared with those of CFs group, expression levels of actin a-SMA and cell proliferation markers protein EDU in the mimics group were significantly lower(P < 0.05); however, expression levels of a-SMA, EDU in the inhibitors group were significantly increased(P < 0.05). Results of qPCR and results of western blotting manifested that compared with those of CFs group, mRNA expression of EGFL7, AKT, pAKT, ERK, pERK and protein expression levels in the mimics group significantly raise, respectively(P < 0.05); but mRNA expression levels of EGFL7, AKT, pAKT, ERK, Perk and protein expression levels in the inhibitor group were significantly lower(P < 0.05). Conclusions: MiR-126 inhibits the proliferation and differentiation of myocardial fibroblasts, possibly through increasing the expression of EGFL7 and activating AKT/ERK signaling pathway.